CoChat
Sign Up
Cited by 27Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.

Epidemiology of Obesity and Pharmacologic Treatment Options

Shettar, Vignesh, Patel, Sarang, Kidambi, Srividya·2017·Nutrition in Clinical Practice
DOI 10.1177/0884533617713189
Open this paper in CoChat — free account

Abstract

Prevalence of obesity and its related morbidity have increased to alarming levels in adults and children in the United States and globally. Weight loss results in improvement of much of the obesity‐related morbidity. Lifestyle changes such as dietary modifications, increased physical activity, and behavioral therapy form the crux of weight management. However, many individuals need additional assistance (pharmacologic or surgical) to initiate or sustain weight loss. Pharmacologic therapy consists of a number of agents that work by decreasing appetite, gastric emptying, or nutrient absorption or by increasing satiety. Five classes of drug are currently approved for adults, including sympathomimetics (with and without an antiepileptic agent topiramate), gastrointestinal lipase inhibitors, serotonin agonists, glucagon‐like peptide 1 agonists, and antidepressant/opioid antagonist combination. Pharmacologic options for children with obesity are minimal (lipase inhibitor orlistat is the only approved medication for children aged >12 years); however, all adult medications are approved by the Food and Drug Administration for children aged >16 years old. While side effect profiles of these medications are far superior to older medications, their use is limited by lack of long‐term cardiovascular safety data, costs of medications and variable insurance coverages, and the need for continued usage for sustainable benefits. Weight loss medications may induce complacence, on part of both the patient and the provider, regarding lifestyle modifications, without which the drug therapy is almost certain to be of minimal benefit. Several novel drugs are in the pipeline targeting brown fat, energy expenditure, appetite suppression, and satiety.

Overview

Integrity signals

Registry

Crossref · 10.1177/0884533617713189

Cites

234 of 234 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 234 references

Research works printed but not linked: 3

  1. Dobbs R, 2015, The Global Obesity Threat
  2. Ryan DA. B, 2014, Handbook of Obesity, 233
  3. 2 new drugs for weight loss, 2012, Med Lett Drugs Ther, 54, 69

Cited by

Sorted by citations

See all 27

Related

Metadata

Authors
Shettar, V., Patel, S., & Kidambi, S.
Affiliations
Medical College of Wisconsin (US)
Corresponding author
Kidambi, Srividya
ORCID
Kidambi, Srividya
Venue
Nutrition in Clinical Practice
Publisher
Wiley
Published
2017-06-20
Volume
32
Issue
4
Pages
441-462
ISSN
  • 0884-5336 (ISSN-L)
  • 1941-2452
DOI
10.1177/0884533617713189
OpenAlex
W2628165181
Cited by
26
References
234
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 7
FWCI
0.52
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nutrition in Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, obesity pharmacotherapy, anti-obesity drugs, obesity prevalence, childhood obesity, sympathomimetic drugs, topiramate, lipase inhibitors, orlistat, serotonin receptor agonists, GLP-1 receptor agonists, lifestyle modification, brown adipose tissue, energy expenditure, adverse drug reactions, cardiovascular safety, obesity-related morbidity
MeSH terms
Diet, Energy Metabolism, Humans, Life Style, Obesity, United States, United States Food and Drug Administration, Meta-Analysis as Topic, Weight Loss, Exercise, Randomized Controlled Trials as Topic, Anti-Obesity Agents, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review